Trial · NCT01453049
Results by group150
Each measurement the trial posted, group by group, in the words and numbers it posted.
81 to 100 of 150
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW | Rosiglitazone+Glimepiride FDC | Platelet count | -5.7 | Standard Deviation 33.73 | Giga per liter (10^9/L) cells |
| Change From Baseline in White Blood Cell (WBC) Count and Platelet Count at Week 24/EW | Glimepiride | Platelet count | 3.4 | Standard Deviation 34.17 | Giga per liter (10^9/L) cells |
| Change From Baseline in Red Blood Cell (RBC) Count at Week 24/EW | Rosiglitazone+Glimepiride FDC | -0.213 | Standard Deviation 0.2577 | Pico per liter (10^12/ L) cells | |
| Change From Baseline in Red Blood Cell (RBC) Count at Week 24/EW | Glimepiride | -0.003 | Standard Deviation 0.2288 | Pico per liter (10^12/ L) cells | |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Rosiglitazone+Glimepiride FDC | Lymphocytes; n=38, 42 | 1.53 | Standard Deviation 5.454 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Glimepiride | Lymphocytes; n=38, 42 | -2.33 | Standard Deviation 5.718 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Rosiglitazone+Glimepiride FDC | Monocytes; n=38, 42 | 0.47 | Standard Deviation 1.345 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Glimepiride | Monocytes; n=38, 42 | -0.33 | Standard Deviation 1.165 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Rosiglitazone+Glimepiride FDC | Neutrophils; n=38, 42 | -2.84 | Standard Deviation 6.059 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Glimepiride | Neutrophils; n=38, 42 | 2.73 | Standard Deviation 6.065 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Rosiglitazone+Glimepiride FDC | Eosinophils; n=35, 42 | 0.61 | Standard Deviation 1.271 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Glimepiride | Eosinophils; n=35, 42 | -0.12 | Standard Deviation 1.116 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Rosiglitazone+Glimepiride FDC | Basophils; n=35, 42 | 0.09 | Standard Deviation 0.255 | percent of WBC count |
| Change From Baseline in Lymphocytes, Monocytes, Neutrophils, Eosinophils, and Basophils at Week 24/EW | Glimepiride | Basophils; n=35, 42 | 0.05 | Standard Deviation 0.473 | percent of WBC count |
| Change From Baseline in Hematocrit (HCT) at Week 24/EW | Rosiglitazone+Glimepiride FDC | -1.21 | Standard Deviation 1.951 | percentage of volume of whole blood | |
| Change From Baseline in Hematocrit (HCT) at Week 24/EW | Glimepiride | 0.52 | Standard Deviation 2.076 | percentage of volume of whole blood | |
| Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW | Rosiglitazone+Glimepiride FDC | HE; n=38, 42 | -3.7 | Standard Deviation 5.81 | Grams per liter (G/L) |
| Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW | Glimepiride | HE; n=38, 42 | 1.5 | Standard Deviation 6.15 | Grams per liter (G/L) |
| Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW | Rosiglitazone+Glimepiride FDC | MCHC; n=35, 42 | -0.2 | Standard Deviation 10.05 | Grams per liter (G/L) |
| Change From Baseline in Hemoglobin (HE), Mean Corpuscular Hemoglobin Concentration (MCHC), Total Protein (TP), and Albumin at Week 24/EW | Glimepiride | MCHC; n=35, 42 | -0.9 | Standard Deviation 11.28 | Grams per liter (G/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01453049/results?page=5